FDA OKs heart valve made from human tissue

Feb 07, 2008

The U.S. Food and Drug Administration has approved the first replacement heart valve made from donated human tissue in which the cells have been removed.

Traditionally, when human tissue is recovered from a cadaver for future implantation, it is inspected, cleaned and decontaminated to prevent infection, but the allograft (human) product remains otherwise unchanged.

The FDA said CryoLife Inc. has added a manufacturing step to its CryoValve SynerGraft Pulmonary Valve and Valved-Conduit Allograft that removes the tissue's cells and cellular debris.

What remains is a scaffold of connective tissue that still functions like a human heart valve, potentially lowering the risk of an immune response and subsequent tissue rejection, the FDA said.

Allograft heart valves are popular choices for children because they avoid the need to take blood-thinning medications on a long-term basis, officials said, and are less likely to calcify than are heart valves from a pig or cow.

The FDA said the SynerGraft valve is for use in patients who require replacement of their pulmonary valve because of disease, malformation or malfunction of their own pulmonary valve, or as part of another surgical procedure.

CryoLife is based in Kennesaw, Ga.

Copyright 2008 by United Press International

Explore further: New drug sales help boost Novartis Q1 profit (Update)

add to favorites email to friend print save as pdf

Related Stories

NASA tests new technologies for robotic refueling

Feb 14, 2014

(Phys.org) —It's corrosive, it's hazardous, and it can cause an explosion powerful enough to thrust a satellite forward in space. Multiple NASA centers are currently conducting a remotely controlled test ...

Robots may receive urine-powered artificial 'hearts'

Nov 27, 2013

(Phys.org) —It's a first: researchers have built the first artificial-heart-like pump that is powered by microbial fuel cells fed on human urine. But instead of being used as a prosthetic device for human ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

New breast cancer imaging method promising

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Breast cancer replicates brain development process

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Research proves nanobubbles are superstable

The intense research interest in surface nanobubbles arises from their potential applications in microfluidics and the scientific challenge for controlling their fundamental physical properties. One of the ...

Using antineutrinos to monitor nuclear reactors

When monitoring nuclear reactors, the International Atomic Energy Agency has to rely on input given by the operators. In the future, antineutrino detectors may provide an additional option for monitoring. ...